Zai Lab

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Zai Lab and other ETFs, options, and stocks.

About ZLAB

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. 

CEO
Ying Du
CEOYing Du
Employees
1,869
Employees1,869
Headquarters
Shanghai, Shanghai
HeadquartersShanghai, Shanghai
Founded
2014
Founded2014
Employees
1,869
Employees1,869

ZLAB Key Statistics

Market cap
1.97B
Market cap1.97B
Price-Earnings ratio
-9.26
Price-Earnings ratio-9.26
Dividend yield
Dividend yield
Average volume
1.05M
Average volume1.05M
High today
$18.13
High today$18.13
Low today
$17.56
Low today$17.56
Open price
$17.74
Open price$17.74
Volume
754.36K
Volume754.36K
52 Week high
$44.34
52 Week high$44.34
52 Week low
$16.82
52 Week low$16.82

Stock Snapshot

As of today, Zai Lab(ZLAB) shares are valued at $17.71. The company's market cap stands at 1.97B, with a P/E ratio of -9.26.

During the trading session on 2025-12-22, Zai Lab(ZLAB) shares reached a daily high of $18.13 and a low of $17.56. At a current price of $17.71, the stock is +0.9% higher than the low and still -2.3% under the high.

Trading volume for Zai Lab(ZLAB) stock has reached 754.36K, versus its average volume of 1.05M.

Over the past 52 weeks, Zai Lab(ZLAB) stock has traded between a high of $44.34 and a low of $16.82.

Over the past 52 weeks, Zai Lab(ZLAB) stock has traded between a high of $44.34 and a low of $16.82.

ZLAB News

Simply Wall St 2d
Zai Lab (NasdaqGM:ZLAB): Valuation Check After First Dosing in Global Phase 1/1b Trial for ZL-1503 - simplywall.st

...

Zai Lab (NasdaqGM:ZLAB): Valuation Check After First Dosing in Global Phase 1/1b Trial for ZL-1503 - simplywall.st
Simply Wall St 3d
How Investors May Respond To Zai Lab Advancing ZL-1503 Into Global Phase 1/1b Atopic Dermatitis Trial

Zai Lab Limited recently dosed the first participant in a global randomized, double-blind, placebo-controlled Phase 1/1b trial of ZL-1503, a potential first-in-...

How Investors May Respond To Zai Lab Advancing ZL-1503 Into Global Phase 1/1b Atopic Dermatitis Trial

Analyst ratings

73%

of 11 ratings
Buy
72.7%
Hold
27.3%
Sell
0%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.